Antitumor Effects of Doxorubicin Against a Virally-Induced Rat Osteosarcoma with Minimal Immunosuppression

References

• Dahlin D. C. Bone Tumors: General Aspects and Data on 6, 221 Cases, 3rd ed. Charles C. Thomas, Springfield, Illinois 1979
   Google Scholar
• Huvos A. G. Bone Tumors: Diagnosis, Treatment, and Prognosis. W.B. Saunders Co., Philadelphia, Pennsylvania 1979
   Google Scholar
• Jaffe N. Recent Advances in the Chemotherapy of Metastatic Osteo-genic Sarcoma. Cancer 1972; 30: 1627
   PubMed Web of Science ®Google Scholar
• Gottlieb J. A., Baker L. H., O'Bryan R. M., Sinkovics J. G., Hoog-Straten B., Quagliana J. J., Rivkin S. E., Bodey G. P., Sr., Rodriguez V. T., Blumenschein G. R., Saiki J. H., Coltman C., Jr., Burgess M. A., Sullivan P., Thigpen T., Bottomley R., Balcerzak S., Moon T. E. Adriamycin (NCI-123127) Used Alone and in Combination for Soft Tissue and Bony Sarcomas. Cancer Chemother. Rep. 1975; 6: 271
   Google Scholar
• Jaffe N., Frei E., III., Traggis D., Cassady J. R., Watts H., Filler R. M. High-Dose Methotrexate with Citrovorum Factor in Qsteogenic Sarcoma-Progress Report II. Cancer Treat. Rep. 1977; 61: 675
   PubMedGoogle Scholar
• Neff J. R., Enneking W. F. Adoptive Immunotherapy in Primary Osteosarcoma. Conflictsin Childhood Cancer, J. O. Godden, L. F. Sinks. Alan R. Liss, New York 1975; 289
   Google Scholar
• Ivins J. C., Ritts R. E., Jr., Prichard D. J., Gilchrist G. S., Miller G. C., Taylor W. F. Transfer Factor Versus Combination Chemotherapy: A Preliminary Report of a Randomized Postsurgical Adjuvant Treatment Study in Osteogenic Sarcoma. Ann. N.Y. Acad. Sci. 1976; 277: 558
   PubMedGoogle Scholar
• Green A. A., Pratt C., Webster R. G., Smith K. Immunotherapy of Osteosarcoma Patients with Virus-Modified Tumor Cells. Ann. N.Y. Acad. Sci. 1976; 277: 396
   PubMedGoogle Scholar
• Wander H., Adamson U., Aparisi T., Brostrom L. A., Cantell K., Einhorn S., Hall K., Ingimarsson S., Nilsonne U., Soderberg G. Adjuvant Interferon Treatment of Human Osteosarcoma. Recent Results Cancer Res. 1978; 68: 40
   PubMedGoogle Scholar
• Copeland M. M. Recent Progress in Chemotherapy and Immunotherapy of Sarcomas of Bony Origin, Both as Primary and Adjunctive Therapy. J. Surg. One. 1977; 9: 2
   PubMedGoogle Scholar
• Vecchi A., Mantovani A., Tagliabue A., Spreafico F. A Characterization of the Immunosuppressive Activity of Adriamycin and Daunomycin on Humoral Antibody Production and Tumor Allograft Rejection. Cancer Res. 1976; 36: 1222
   PubMed Web of Science ®Google Scholar
• Orsini F., Pavelic Z., Mihich E. Increased Primary Cell-mediated Immunity in Culture Subsequent to Adriamycin or Daunorubicin Treatment of Spleen Donor Mice. Cancer Res. 1977; 37: 1719
   PubMed Web of Science ®Google Scholar
• Mantovani A. In Vitro and In Vivo Cytotoxicity of Adriamycin and Daunomycin for Murine Macrophages. Cancer Res 1977; 37: 815
   PubMed Web of Science ®Google Scholar
• Roth J. A., Eilber F. R., Morton D. L. Effect of Adriamycin and High-Dose Methotrexate Chemotherapy on in Vivo and in Vitro Cell-Mediated Immunity in Cancer Patients. Cancer 1978; 41: 814
   PubMed Web of Science ®Google Scholar
• Friedlaender G. E., Mitchell M. S. A Laboratory Model for the Study of the Immunobiology of Osteosarcoma. Cancer 1975; 36: 1631
   PubMedGoogle Scholar
• Friedlaender G. E., Mitchell M. S. A Virally Induced Osteosarcoma in Rats. J. Bone Joint Surgery 1976; 58A(3)295
   Google Scholar
• Urovitz E. P., Czitrom A. A., Langer F., Gross A. E., Pritzker K. P.H. Immunogenicity of Virus-Induced Rat Osteosarcoma. J. Bone Joint Surgery 1976; 58A(3)309
   Google Scholar
• Moloney J. B. Biological Studies on a Lymphoid-Leukemia Virus Extracted from Sarcoma 37.1. Origin and Introductory Investigations. J. Natl. Cancer Inst. 1960; 24: 933
   PubMedGoogle Scholar
• Takasugi M., Klein E. A Microassay for Cell-mediated Immunity. Transplant. 1970; 9: 219
   PubMedGoogle Scholar
• Singh I., Tsang K. Y., Blakemore W. S. Immunologic Studies in Contacts of Osteosarcoma in Humans and Animals. Nature 1977; 265(5594)541
   PubMedGoogle Scholar
• Cohen A. M., Ketcham AS., Morton D. L. Tumor-Specific Cellular Cytotoxicity to Human Sarcomas: Evidence for a Cell-Mediated Host Immune Response to Common Sarcoma Cell-Surface Antigen. J. Natl. Cancer Inst. 1973; 50(3)585
   PubMedGoogle Scholar
• Kessel D. Enhanced Glycosylation Induced by Adriamycin. Molec. Pharm. 1979; 16: 306
   PubMed Web of Science ®Google Scholar
• Fefer A., McCoy J. L., Perk K., Glynn J. P. Immunologic, Virologic, and Pathologic Studies of Regression of Autochthonous Moloney Sarcoma Virus-induced Tumors in Mice. Cancer Res. 1968; 28: 1577
   PubMedGoogle Scholar
• Berenson J. R., Einstein A. B., Fefer A. Syngeneic Adoptive Immuno-therapy and Chemoimmunotherapy of a Friend Leukemia: Requirement for T Cells. J. Immunol. 1975; 115: 234
   PubMedGoogle Scholar
• Stutman O., Shen F. W. Postthymic Precursor Cells Give Rise to Both Lyt-1 and Lyt-23 Subsets of T Cells. Transplant. Proceedings 1979; 11(1)907
   PubMedGoogle Scholar
• Dlugi A. M., Robie K. M., Mitchell M. S. Failure of Bleomycin to Affect Humoral or Cell-mediated Immunity in the Mouse. Cancer Res. 1974; 34: 2504
   PubMed Web of Science ®Google Scholar
• Kolb H. J., Storb R., Weiden P. L., Ochs H. D., Kolb H., Graham T. C., Floersheim G. L., Thomas E. D. Immunologic, Toxicologic and Marrow Transplantation Studies in Dogs Given Dimethyl Myleran. Biomedicine 1974; 20: 341
   PubMedGoogle Scholar
• Bruckner H. W., Mokyr M. B., Mitchell M. S. Effect of Imidazole-4-carboxamide, 5–(3, 3-Dimethyl-l-triazeno) on Immunity in Patients with Malignant Melanoma. Cancer Res 1974; 34: 181
   PubMed Web of Science ®Google Scholar